INAB IN8BIO, INC.

IN8bio, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. It is conducting two investigator-initiated Phase 1 clinical product candidates comprising INB-200, a genetically modified autologous gamma-delta T cell product candidate for the treatment of solid tumors; and INB-100, an allogeneic product candidate for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was founded in 2016 and is based in New York, New York.

$8.09
As of 09/16/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  07/30/2021
Outstanding shares:  18,754,553
Average volume:  34,127
Market cap:   $151,724,334
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy